Neos Therapeutics Inc. (NEOS) Plunges 7.97% on March 27

Neos Therapeutics Inc. (NEOS) Plunges 7.97% on March 27

Neos Therapeutics Inc. (NEOS) had a rough trading day for Wednesday March 27 as shares tumbled 7.97%, or a loss of $-0.24 per share, to close at $2.77. After opening the day at $3.04, shares of Neos Therapeutics Inc. traded as high as $3.04 and as low as $2.71. Volume was 373,004 shares over 1,635 trades, against an average daily volume of n/a shares and a total float of 49.71 million.

As a result of the decline, Neos Therapeutics Inc. now has a market cap of $137.7 million. In the last year, shares of Neos Therapeutics Inc. have traded between a range of $8.70 and $1.40, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through United States and derives revenue through sale of products.

Neos Therapeutics Inc. is based out of Grand Prairie, TX and has some 215 employees.

Share:
Scroll Up
error: Content is protected !!